AstraZeneca

AstraZeneca and Daiichi's Datroway (Dato-DXd) Approved for Triple-Negative Breast Cancer: Implications for Pharma

FDA · breast cancer · 5 min

The FDA approved AstraZeneca and Daiichi Sankyo's Datroway (Dato-DXd) as a first-line treatment for triple-negative breast cancer on May 1, 2026. This article provides key takeaways, regulatory details, and strategic implications for pharma decision-makers.

Owkin and AstraZeneca Enhance AI Collaboration for Drug Research

FDA · 4 min

Owkin and AstraZeneca have expanded their collaboration to develop AI-driven drug research tools, aiming to accelerate clinical trials and reduce costs. This deal intelligence article provides key takeaways, regulatory implications, and an FAQ section for pharma teams and investors.

Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients

FDA · breast cancer · 7 min

The FDA has granted Priority Review to Datroway for the treatment of metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation marks a significant step for AstraZeneca and offers a potential new therapeutic avenue for a challenging cancer subtype.

FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

FDA · hypertension · 7 min

The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.

ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address

7 min

The ASCO 2026 annual meeting presented a subdued landscape for European pharmaceutical giants like AstraZeneca and Roche, highlighting areas where both companies need to intensify their strategic efforts. Despite a quiet conference, significant market dynamics are at play for these oncology leaders.

FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights

FDA · breast cancer · 2 min

The FDA has delayed the review of AstraZeneca's breast cancer drug, raising questions about the future of the drug and its market impact. Here's what you need to know.

IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer

FDA · oncology · 2 min

AstraZeneca's IMFINZI® (durvalumab) has received FDA approval as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options.

Imfinzi Receives FDA Approval for Bladder Cancer Treatment

FDA · oncology · 2 min

AstraZeneca's Imfinzi has been approved by the FDA for a new indication in bladder cancer treatment. This approval opens new avenues for investment and market competition.